Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

HEPINIB · Heparanase inhibition as a multifunctional targeting approach in cancer

HORIZONStatus: SIGNED1 January 202331 December 2026EU funding €437,000Call HORIZON-MSCA-2021-SE-01

Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell nichesallow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteins substituted with the heparin-related carbohydrate heparan sulfate (HS) are dysregulated in malignant diseases, and are known to modulate all of the aforementioned processes of tumor progression. Several functions of HS-PGs in tumor progression are modulated by the enzymeheparanase (HPSE), which is barely expressed in adults, but upregulated during tumor progression, inflammation and angiogenesis, thus constituting an excellent drug target. Indeed, HPSE, the sole HS degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis and inflammation. HPSE accomplishes this by degrading HS and thereby regulating the bioavailability of heparin-binding proteins, priming the tumor microenvironment and mediating tumor-host crosstalk. We predict that therapeutic targeting of HPSE to be superior to conventional approaches, as it does not only have the potential to synchronously targeting tumor progression and metastasis at multiple levels (metastasis, angiogenesis, inflammation & immunity), but it is also be expected to have a favourable side effects profile. HEPINIB will combine leading experts of HPSE-related cancer research with non-academic partners providing a panel of innovative technologies with the aims of providing a deeper understanding of HPSE function in tumor progression, of developing novel HPSE inhibitors and delivery systems, and of trans-sectoral and interdisciplinary training of young scientists.

Consortium · 14 organisations

coordinator

UNIVERSITAET MUENSTER

DE · €55,200

participant

CENTRO ALTA TECNOLOGIA ISTITUTO DIRICERCHECHIMICHE E BIOCHIMICHE GRONZONI SRL

IT · €18,400

associatedPartner

CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET)

AR

participant

UPPSALA THERAPEUTICS AB

SE · €13,800

participant

UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE

FR · €55,200

participant

ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICA G. RONZONI

IT · €23,000

participant

UPPSALA UNIVERSITET

SE · €27,600

participant

LEAD DISCOVERY CENTER GMBH

DE · €4,600

participant

RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN

DE · €50,600

participant

CONSIGLIO NAZIONALE DELLE RICERCHE

IT · €41,400

participant

SEREND-IP GMBH

DE · €32,200

participant

POLITECNICO DI MILANO

IT · €50,600

participant

CELVIA CC AS

EE · €55,200

participant

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

IL · €9,200

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.